金域医学(603882) - 2024 Q3 - 季度财报

Financial Performance - Revenue for the third quarter was RMB 1.74 billion, a decrease of 13.15% year-over-year[2] - Net profit attributable to shareholders for the third quarter was RMB 4.19 million, a significant decrease of 98.56% year-over-year[2] - Revenue for the first nine months of 2024 was RMB 5.62 billion, down 10.95% year-over-year[2] - Net profit attributable to shareholders for the first nine months was RMB 93.84 million, a decrease of 83.71% year-over-year[2] - Total revenue for the first three quarters of 2024 was 5,618,852,446.76 RMB, a decrease from 6,309,622,119.42 RMB in the same period of 2023[16] - Total operating costs for the first three quarters of 2024 were 5,117,588,587.38 RMB, down from 5,575,699,748.49 RMB in the same period of 2023[16] - Net profit for the first three quarters of 2024 was 83,867,861.65 RMB, significantly lower than 566,649,689.09 RMB in the same period of 2023[18] - Net profit attributable to parent company shareholders was RMB 93.84 million, compared to RMB 576.02 million in the same period last year[19] - Comprehensive income attributable to parent company shareholders was RMB 90.79 million, compared to RMB 591.26 million in the same period last year[19] - Basic earnings per share were RMB 0.20, compared to RMB 1.23 in the same period last year[19] Cash Flow and Liquidity - Operating cash flow for the first nine months was RMB 311.92 million, down 38.58% year-over-year[3] - Cash received from sales of goods and services was RMB 5.48 billion, a decrease from RMB 6.94 billion in the same period last year[20] - Net cash flow from operating activities was RMB 311.92 million, compared to RMB 507.81 million in the same period last year[20] - Net cash flow from investing activities was negative RMB 361.42 million, compared to negative RMB 484.14 million in the same period last year[22] - Net cash flow from financing activities was negative RMB 463.11 million, compared to negative RMB 912.54 million in the same period last year[22] - Cash and cash equivalents at the end of the period were RMB 1.94 billion, a decrease from RMB 2.04 billion at the end of the same period last year[22] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 10.98 billion, a decrease of 6.71% compared to the end of the previous year[3] - The company's monetary funds as of September 30, 2024, amounted to 1,944,019,325.90, a decrease from 2,457,662,736.68 at the end of 2023[13] - Accounts receivable as of September 30, 2024, were 5,115,653,178.99, slightly down from 5,335,343,742.15 at the end of 2023[13] - Inventory as of September 30, 2024, was 219,728,110.68, a decrease from 248,207,375.35 at the end of 2023[13] - Fixed assets as of September 30, 2024, were 1,490,768,451.49, down from 1,658,412,561.01 at the end of 2023[13] - Construction in progress as of September 30, 2024, was 444,154,863.79, an increase from 359,106,431.46 at the end of 2023[13] - The company's total current assets as of September 30, 2024, were 7,602,529,177.22, down from 8,265,141,988.72 at the end of 2023[13] - Total assets as of Q3 2024 were 10,978,237,374.03 RMB, compared to 11,767,672,448.57 RMB at the end of 2023[14] - Total liabilities as of Q3 2024 were 2,965,165,339.17 RMB, down from 3,220,280,284.46 RMB at the end of 2023[15] - Accounts payable increased to 1,782,901,091.66 RMB in Q3 2024 from 2,065,125,244.77 RMB at the end of 2023[14] - Long-term loans increased to 438,816,493.70 RMB in Q3 2024 from 267,612,098.21 RMB at the end of 2023[14] - Deferred tax assets increased to 236,494,780.86 RMB in Q3 2024 from 151,106,249.77 RMB at the end of 2023[14] - Total equity attributable to owners of the parent company was 7,831,588,638.03 RMB in Q3 2024, down from 8,362,834,963.48 RMB at the end of 2023[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 34,066[8] - Liang Yaoming, a domestic natural person, holds 74,191,907 shares, accounting for 15.83% of the total shares[8] - Hong Kong Securities Clearing Company Limited holds 47,392,211 shares, accounting for 10.11% of the total shares[8] Business Development and Innovation - The company added 25 new precision medicine centers and 20 new industry-academia collaborations and disease alliances in the first nine months of 2024[7] - The company launched 4 products on the Guangzhou Data Exchange and won the "Commercial Value Award" at the 2024 "Data Element ×" competition[7] - The company continues to deepen its digital transformation, leveraging AI technologies to enhance medical testing data potential[7] Research and Development - R&D expenses for the first three quarters of 2024 were 302,366,808.51 RMB, a decrease from 365,465,783.65 RMB in the same period of 2023[18]